What You Should Know:
– WeightWatchers, the global leader in science-backed weight management, announced a expansion of its collaboration with Novo Nordisk that will increase access to authentic, FDA-approved Wegovy® (semaglutide) injection through WeightWatchers Clinic.
– The collaboration aims to simplify the prescription process, enhance affordability, and explore real-world research initiatives to improve long-term outcomes for individuals managing their weight.
Streamlined Access and Affordability for Members
As part of the expanded collaboration, WeightWatchers Clinic members will benefit from a simplified prescription process via NovoCare® Pharmacy. CenterWell Pharmacy®, a seven-time MMIT Specialty Pharmacy Patient Choice Award winner, will serve as the dispensing pharmacy for the NovoCare® program. This will facilitate direct fulfillment and home delivery of Wegovy® prescriptions for WeightWatchers Clinic members.
In addition to simplified delivery, WeightWatchers will enhance the member experience by providing integrated account access, bundled pricing opportunities, inventory visibility, and shipment tracking.
To further expand access, Novo Nordisk is offering a limited-time savings offer. Starting July 1, 2025, eligible cash-pay members of WeightWatchers Clinic can access Wegovy® at a reduced price of $299 until July 31, 2025. This significant saving is aimed at broadening access to clinically validated, FDA-regulated treatment options.
Real-World Research and Clinical Impact
WeightWatchers and Novo Nordisk will also explore opportunities for further collaboration on real-world research initiatives and strategies to improve long-term outcomes. The aim is to evaluate the potential impact of combining Wegovy®, the most widely used GLP-1 medication globally, with WeightWatchers’ nutrition and behavioral support program, to demonstrate the clinical and economic value of this integrated care model.
Wegovy®, first approved in 2021, is the only FDA-approved semaglutide treatment for weight loss. It transformed obesity treatment as the first weekly GLP-1 for chronic weight management and currently supports nearly 1.5 million patients in the U.S.. In 2024, the FDA expanded Wegovy®’s label to include an indication for reducing the risk of major cardiovascular events in adults with known heart disease and either obesity or overweight.
Preliminary real-world evidence is promising: a study of 3,260 WeightWatchers Clinic members prescribed a GLP-1 showed participants lost an average of 21% of their body weight at 12 months, indicating that combining a GLP-1 with WeightWatchers’ holistic support model can deliver superior, sustainable outcomes.
Scott Honken, Chief Commercial Officer at WeightWatchers, stated, “By deepening our collaboration with Novo Nordisk, we are helping more people access the FDA-approved treatment they deserve, delivered within a holistic clinical model proven to support real, sustainable and improved health outcomes”. He emphasized that WeightWatchers “remains the trusted leader, bringing together access to safe, FDA-approved medication and best-in-class lifestyle support, setting the bar for the gold standard of responsible weight management”.
